Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros











Intervalo de año de publicación
1.
PLoS One ; 19(9): e0310274, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39250492

RESUMEN

Meningococcal vaccination in Chinese national immunization program (NIP) includes polysaccharide vaccine against Neisseria meningitidis serogroup A (MPV-A) and polysaccharide vaccine against Neisseria meningitidis serogroup A and C(MPV-AC). This study aimed to assess the cost-effectiveness of an alternative strategy using polysaccharide conjugate vaccine against Neisseria meningitidis serogroup A,C,W,Y(MCV-ACWY) and polysaccharide vaccine against Neisseria meningitidis serogroup A,C,W,Y(MPV-ACWY). From a societal perspective, we constructed a decision tree-Markov model to simulate the economic and health consequences of meningococcal disease in a 2023 birth cohort with the current meningococcal vaccination strategy and the alternative. Parameters of epidemiology, vaccine efficacy, cost, and utility were extracted from database and previous literatures. The sensitivity analysis was implemented to evaluate the robustness of the model. Compared to the current practice, the alternative strategy could avoid 513 meningococcal disease cases, 53 sequelae and 47 deaths. The ICER was estimated at $16899.81 /QALY, under the threshold of one time of the GDP per capita of Zhejiang province in 2023. The incidence of meningococcemia, the incidence of meningococcal meningitis, the case fatality of meningococcemia, the vaccine efficacy of MCV-ACWY and the price of MCV-ACWY would influence the cost-effectiveness of the meningococcal vaccination strategies. At the threshold, the probability of cost-effectiveness was 14.76% for the current strategy and 55.98% for the alternative strategy, respectively. The current meningococcal vaccination strategy had effectively prevented meningococcal disease at a low cost, but with limited serogroup coverage. Strategy using MCV-ACWY and MPV-ACWY could increase health benefits at a substantial cost at a cost-effective manner.


Asunto(s)
Análisis Costo-Beneficio , Infecciones Meningocócicas , Vacunas Meningococicas , Vacunación , Humanos , Vacunas Meningococicas/economía , Vacunas Meningococicas/administración & dosificación , China/epidemiología , Infecciones Meningocócicas/prevención & control , Infecciones Meningocócicas/epidemiología , Infecciones Meningocócicas/economía , Lactante , Niño , Preescolar , Vacunación/economía , Programas de Inmunización/economía , Femenino , Masculino , Neisseria meningitidis/inmunología , Años de Vida Ajustados por Calidad de Vida
2.
PLoS One ; 19(5): e0303508, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38768133

RESUMEN

PURPOSE: The resurgence of pertussis has occurred around the world. However, the epidemiological profiles of pertussis cannot be well understood by current diseases surveillance. This study was designed to understand the seroepidemiological characteristics of pertussis infection in the general population of Huzhou City, evaluate the prevalence infection of pertussis in the population, and offer insights to inform adjustments in pertussis prevention and control strategies. METHODS: From September to October 2023, a cross-sectional serosurvey was conducted in Huzhou City, involving 1015 permanent residents. Serum samples were collected from the study subjects, and pertussis toxin IgG antibodies (Anti-PT-IgG) were quantitatively measured using enzyme-linked immunosorbent assay (ELISA). The analysis included the geometric mean concentration (GMC) of Anti-PT-IgG, rates of GMC≥40IU/mL, ≥100IU/mL, and <5IU/mL. Stratified comparisons were made based on age, vaccination history, and human categories. RESULTS: Among the 1015 surveyed individuals, the geometric mean concentration (GMC) of Anti-PT-IgG was 10.52 (95% CI: 9.96-11.11) IU/mL, with a recent infection rate of 1.58%, a serum positivity rate of 11.43%, and a proportion with <5IU/mL of 40.49%. Among 357 children with clear vaccination history, susceptibility decreased with an increasing number of vaccine doses (Z = -6.793, P < 0.001). The concentration of Anti-PT-IgG exhibited a significant post-vaccination decline over time (Z = -5.143, P < 0.001). In women of childbearing age, the GMC of Anti-PT-IgG was 7.71 (95% CI: 6.90-8.62) IU/mL, with no significant difference in susceptibility among different age groups (χ2 = 0.545, P = 0.909). The annual pertussis infection rate in individuals aged ≥3 years was 9321 (95%CI: 3336-16039) per 100,000, with peak infection rates in the 20-29, 40-49, and 5-9 age groups at 34363 (95%CI: 6327-66918) per 100,000, 22307.72 (95%CI: 1380-47442) per 100,000, and 18020(95%CI: 1093-37266) per 100,000, respectively. CONCLUSIONS: In 2023, the actual pertussis infection rate in the population of Huzhou City was relatively high. Vaccine-induced antibodies exhibit a rapid decay, and the estimated serum infection rate increases rapidly from post-school age, peaking in the 20-29 age group. It is recommended to enhance pertussis monitoring in adolescents and adults and refine vaccine immunization strategies.


Asunto(s)
Anticuerpos Antibacterianos , Inmunoglobulina G , Tos Ferina , Humanos , Tos Ferina/epidemiología , Tos Ferina/sangre , Tos Ferina/inmunología , Tos Ferina/prevención & control , Femenino , Estudios Transversales , Adulto , Masculino , China/epidemiología , Estudios Seroepidemiológicos , Niño , Persona de Mediana Edad , Adolescente , Preescolar , Adulto Joven , Lactante , Inmunoglobulina G/sangre , Anticuerpos Antibacterianos/sangre , Anciano , Toxina del Pertussis/inmunología , Prevalencia , Vacuna contra la Tos Ferina/inmunología , Vacunación , Bordetella pertussis/inmunología
3.
Journal of Preventive Medicine ; (12): 701-704, 2023.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-980338

RESUMEN

Objective@# To investigate the incidence of adverse events following immunization (AEFI) with inactivated influenza vaccine among the elderly in Huzhou City, Zhejiang Province, so as to provide insights into safety monitoring and evaluation of inactivated influenza vaccines.@*Methods@#Data pertaining to surveillance on AEFI with inactivated influenza vaccines among the elderly at ages of 60 years and older in Huzhou City from 2020 to 2022 were collected from the AEFI Monitoring Information Management System of the Immunization Planning System of Chinese Disease Control and Prevention Information System, including demographics, time of AEFI occurrence, classification of AEFI and clinical syndromes, and the reported incidence and epidemiological features of AEFI with inactivated influenza vaccines were analyzed using a descriptive epidemiological method. @*Results@#Totally 84 elderly cases at ages of 60 years and older were reported with AEFI with inactivated influenza vaccines in Huzhou City from 2020 to 2022, with a reported incidence rate of 9.83/105 doses, and the reported incidence rates of AEFI with trivalent and quadrivalent inactivated influenza vaccines were 9.74/105 doses and 48.71/105 doses, respectively. The reported incidence rates of general, abnormal, coincidence and psychogenic reactions were 7.96/105 doses, 1.52/105 doses, 0.23/105 doses and 0.12/105 doses, respectively, and no vaccine quality accidents or wrong vaccine administered were reported. The cases with AEFI included 52 women and 32 men, and most cases were aged from 60 to 69 years (44 cases, 52.38%). The highest incidence of AEFI was reported in Nanxun District (17.94/105 doses), and there were 79 cases (94.05%) with AEFI within 24 hours following vaccination. The clinical symptoms mainly included fever, local redness and swelling, and local induration, with reported incidence rates of 2.22/105 doses, 3.74/105 doses, and 1.99/105 doses, respectively.@*Conclusions@#The reported incidence of AEFI with inactivated influenza vaccines is low among the elderly at ages of 60 years and older in Huzhou City, with general reactions as predominant AEFI, and most AEFI occurs within 24 hours following vaccination.

4.
Journal of Preventive Medicine ; (12): 339-341, 2023.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-971799

RESUMEN

Objective@#To investigate the incidence of allergic rash associated with vaccination in Huzhou City from 2017 to 2021, so as to provide insights into the prevention and control of allergic rash. @*Methods@#Data pertaining to cases with vaccination-related allergic rash in Huzhou City from 2017 to 2021 were captured from the National Adverse Events Following Immunization Surveillance System of Chinese Disease Control and Prevention Information System, and epidemiological characteristics, vaccination and clinical features of allergic rash were analyzed.@*Results@#Totally 324 allergic rash cases were reported in Huzhou City from 2017 to 2021, with an annual reported incidence of 6.12/105 doses. The incidence of allergic rash was 6.40/105 doses among men and 5.82/105 doses among women, and allergic rash predominantly occurred among cases under 1 year, with a reported incidence of 8.32/105 doses. The largest number of cases was reported in the second quarter (108 cases, 33.33%), and the largest number of cases was reported in Deqing County (92 cases, 28.40%) with a reported incidence of 11.52/105 doses. The highest reported incidence of allergic rash was seen following immunization with combined live-attenuated measles-mumps-rubella vaccines (41.23/105 doses). There were 203 cases (62.65%) diagnosed as allergic rash, 55 cases (16.98%) diagnosed as urticaria, 51 cases (15.74%) diagnosed as measles scarlet fever-like rash, and 15 cases (4.63%) diagnosed as maculopapule. There were 94 (29.01%) cases with fever, and 78.70% allergic rash occurred within 24 hours of vaccination.@*Conclusion@#The incidence of allergic rash associated with vaccination was high in Huzhou City from 2017 to 2021, and vaccination-related allergic rash predominantly occurred within 24 hours following immunization with the first dose of vaccines. Allergic rash associated with vaccination was highly prevalent among children under 1 year.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA